Nipride

(nitroprusside)

Phase 2Small molecule

EExela Pharma Sciences, LLC.

Nipride is one of 104 small molecule programs targeting Aortic Coarctation. It is currently in Phase 2.

Indications

Total Trials

Active Trials

103

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Aortic CoarctationActive, not recruiting

Acute Myocardial InfarctionActive, not recruiting

Uterine FibroidActive, not recruiting

HypotensionActive, not recruiting

Aortic CoarctationPhase 2

Active, not recruiting

Acute Myocardial InfarctionPhase 2/Phase 3

Active, not recruiting

Uterine FibroidPreclinical

Active, not recruiting

HypotensionPreclinical

Active, not recruiting

Competition

Competitive Landscape

216 competitors in Acute Myocardial Infarction

#DrugCompanyPhaseTrials

Farxiga

AstraZeneca

Phase 3

4 2

Lovenox

Sanofi

Phase 3

2 3

Byetta

AstraZeneca

Phase 3

1 4

Lovenox

Sanofi

Phase 3

1 5

Kineret

SSwedish Orphan Biovitrum

Phase 3

2 6

Glucophage

EMD Serono

Phase 3

1 7

Allegra

CChattem

Phase 3

1 8

Cyclosporine a

Novartis

Phase 3

1 9

Unfractionated Heparin

GSK

Phase 3

1 10

Control - UFH

GSK

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Aging

NCT06520982

Clinical

Trials by Indication[1]

Hypotension2 trials

Remifentanil and Nitroprusside for Controlled Hypotension

Completed·—·N/A·NCT02001298·30 enrolled

Dose-response Study of Sodium Nitroprusside in Children Requiring Controlled Hypotension in the Operating Room

Completed·TThe Emmes Company, LLC·Phase 2·NCT00135668·211 enrolled

Blood Pressure2 trials

Sodium Nitroprusside for Blood Pressure Reduction in the ICU (SNP2)

Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2·NCT00621816·45 enrolled

Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage

Completed·TThe George Institute·N/A·NCT00226096·404 enrolled

Acute Myocardial Infarction1 trial

THE REOPEN-AMI STUDY - Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction

Completed·—·Phase 2/3·NCT00590070·240 enrolled

Aortic Coarctation1 trial

Effect of Strategy for Blood Pressure Control on Cerebral Oxygen Balance During Aortic Coarctation Repair: A Randomized Study

Completed·UUniversity Hospital, Ghent·Phase 2·NCT00535808·30 enrolled

Vasodilation1 trial

Bevacizumab and Endothelium Dependent Vasodilation

Completed·RRadboud University Medical Center·N/A·NCT01125943·24 enrolled

4 more indications

Depression1 trial

Ketamine and Nitroprusside for Depression

Completed·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT03102736·40 enrolled

Aging1 trial

Early Neurovascular Adaptations in Aging Women

Recruiting·UUniversity of Missouri-Columbia·Phase 1·NCT06520982·64 enrolled

Prevention1 trial

Nitroprusside for Prevention of no-Reflow in Primary Angioplasty

Terminated·SSoroka University Medical Center·Phase 4·NCT00128791·100 enrolled

Uterine Fibroid1 trial

Vascular Function and Uterine Fibroids

Completed·MMayo Clinic··NCT02123069·28 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

NIPRIDE

NDA NDA017546

Jan 1, 1982

NITROPRESS

NDA NDA018450

Jul 28, 1982

SODIUM NITROPRUSSIDE

NDA NDA018581

Dec 7, 2017

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

NDA NDA209387

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for nitroprusside. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — nitroprusside compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for nitroprusside. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA209387). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Exela Pharma Sciences, LLC. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EExela Pharma Sciences, LLC.

Nipride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Hypotension2 trials

Blood Pressure2 trials

Acute Myocardial Infarction1 trial

Aortic Coarctation1 trial

Vasodilation1 trial

Depression1 trial

Aging1 trial

Prevention1 trial

Uterine Fibroid1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News